At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Clofarabine, AraC, mitoxantrone (CLAM)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML
In Brief
A Phase 2 clinical trial evaluating Clofarabine, AraC, mitoxantrone (CLAM) for Acute Myeloid Leukemia. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The study aims to evaluate the efficacy of the regimen CLAM in relapsed or refractory AML when used as first salvage for patients to relapse or fail after standard treatment with daunorubicin/cytarabine induction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesHong Kong
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedFeb 2016
Primary CompletionMar 2018
Study CompletionMay 2018
TodayJul 2026
First PostedFeb 19, 2016
Enrollment StartFeb 1, 2016
Primary CompletionMar 31, 2018
Study CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.4 years ago
Interventions
Clofarabine, AraC, mitoxantrone (CLAM)drug
The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage